+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Amyloidogenic and non-amyloidogenic transthyretin Asn 90 variants



Amyloidogenic and non-amyloidogenic transthyretin Asn 90 variants



Clinical Genetics 42(1): 27-30



Recently, a new transthyretin (TTR) variant was described in the normal Portuguese and German populations. The same substitution was found associated with familial amyloidotic polyneuropathy (FAP) in an American family of Italian origin. Comparative isoelectric focusing studies showed a difference in the mobility pattern between the non-pathogenic and pathogenic variants. However, comparative DNA sequencing between them did not reveal any additional mutation. Comparative isoelectric focusing between the variants and TTR Asn 90 produced by recombinant techniques indicated that the non-pathogenic variant has the electrophoretic behaviour expected for the mutation. We suggest that an as yet unknown post-translational modification may have occurred in the FAP-associated Asn 90 variant, turning it into an amyloidogenic molecule.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 039234364

Download citation: RISBibTeXText

PMID: 1355416

DOI: 10.1111/j.1399-0004.1992.tb03131.x


Related references

Comparative calorimetric study of non-amyloidogenic and amyloidogenic variants of the homotetrameric protein transthyretin. Biophysical Chemistry 88(1-3): 61-67, 2000

Comparative calorimetric study of non-amyloidogenic and amyloidogenic variants of the homotetrameric protein transthyretin. Biophysical Chemistry 88(1-3): 61-67, 15 December, 2000

Tertiary structures of amyloidogenic and non-amyloidogenic transthyretin variants: new model for amyloid fibril formation. Amyloid 5(3): 175-187, 1998

Amyloidogenic and anti-amyloidogenic properties of recombinant transthyretin variants. Amyloid 11(1): 1-9, 2004

Amyloidogenic and non-amyloidogenic transthyretin variants interact differently with human cardiomyocytes: insights into early events of non-fibrillar tissue damage. Bioscience Reports 35(1):, 2015

Trapping the monomer of a non-amyloidogenic variant of transthyretin: exploring its possible use as a therapeutic strategy against transthyretin amyloidogenic diseases. Journal of Biological Chemistry 284(3): 1443-1453, 2009

Transthyretin and BRICHOS: The Paradox of Amyloidogenic Proteins with Anti-Amyloidogenic Activity for Aβ in the Central Nervous System. Frontiers in Neuroscience 11: 119, 2017

Transthyretin Asn90 variant: amyloidogenic or non-amyloidogenic role. Journal of the Neurological Sciences 284(1-2): 113-115, 2009

The preaggregated state of an amyloidogenic protein: hydrostatic pressure converts native transthyretin into the amyloidogenic state. Proceedings of the National Academy of Sciences of the United States of America 97(12): 6445-6450, 2000

Amyloidogenic potential of transthyretin variants: insights from structural and computational analyses. Journal of Biological Chemistry 284(38): 25832-25841, 2009

The amyloidogenic potential of transthyretin variants correlates with their tendency to aggregate in solution. FEBS Letters 418(3): 297-300, 1997

The amyloidogenic potential of transthyretin variants correlates with their tendency to aggregate in solution. Febs Letters 418(3): 297-300, 1997

An on-line assay for clinical detection of amyloidogenic transthyretin variants directly from serum. Amyloid 10(3): 190-197, 2003

Inhibition of intracellular tetramerization induces the proteasomal degradation of amyloidogenic transthyretin variants. 2008

Antibody recognition of amyloidogenic transthyretin variants in serum of patients with familial amyloidotic polyneuropathy. Journal of the Peripheral Nervous System 7(2): 134-134, 2002